| First Author | El-Merahbi R | Year | 2020 |
| Journal | Genes Dev | Volume | 34 |
| Issue | 7-8 | Pages | 495-510 |
| PubMed ID | 32139423 | Mgi Jnum | J:292510 |
| Mgi Id | MGI:6448776 | Doi | 10.1101/gad.333617.119 |
| Citation | El-Merahbi R, et al. (2020) The adrenergic-induced ERK3 pathway drives lipolysis and suppresses energy dissipation. Genes Dev 34(7-8):495-510 |
| abstractText | Obesity-induced diabetes affects >400 million people worldwide. Uncontrolled lipolysis (free fatty acid release from adipocytes) can contribute to diabetes and obesity. To identify future therapeutic avenues targeting this pathway, we performed a high-throughput screen and identified the extracellular-regulated kinase 3 (ERK3) as a hit. We demonstrated that beta-adrenergic stimulation stabilizes ERK3, leading to the formation of a complex with the cofactor MAP kinase-activated protein kinase 5 (MK5), thereby driving lipolysis. Mechanistically, we identified a downstream target of the ERK3/MK5 pathway, the transcription factor FOXO1, which promotes the expression of the major lipolytic enzyme ATGL. Finally, we provide evidence that targeted deletion of ERK3 in mouse adipocytes inhibits lipolysis, but elevates energy dissipation, promoting lean phenotype and ameliorating diabetes. Thus, ERK3/MK5 represents a previously unrecognized signaling axis in adipose tissue and an attractive target for future therapies aiming to combat obesity-induced diabetes. |
